175 related articles for article (PubMed ID: 23598480)
21. The introduction of new vaccines into developing countries. IV: Global Access Strategies.
Mahoney RT; Krattiger A; Clemens JD; Curtiss R
Vaccine; 2007 May; 25(20):4003-11. PubMed ID: 17363119
[TBL] [Abstract][Full Text] [Related]
22. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization.
Amarasinghe A; Black S; Bonhoeffer J; Carvalho SM; Dodoo A; Eskola J; Larson H; Shin S; Olsson S; Balakrishnan MR; Bellah A; Lambach P; Maure C; Wood D; Zuber P; Akanmori B; Bravo P; Pombo M; Langar H; Pfeifer D; Guichard S; Diorditsa S; Hossain MS; Sato Y
Vaccine; 2013 Apr; 31 Suppl 2():B108-14. PubMed ID: 23598471
[TBL] [Abstract][Full Text] [Related]
23. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
24. Technology transfer in human vaccinology: a retrospective review on public sector contributions in a privatizing science field.
Hendriks J
Vaccine; 2012 Sep; 30(44):6230-40. PubMed ID: 22902679
[TBL] [Abstract][Full Text] [Related]
25. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
[TBL] [Abstract][Full Text] [Related]
26. The role of emerging manufacturers in access to innovative vaccines of public health importance.
Milstien JB; Kaddar M
Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054
[TBL] [Abstract][Full Text] [Related]
27. Vaccine shortages: history, impact, and prospects for the future.
Hinman AR; Orenstein WA; Santoli JM; Rodewald LE; Cochi SL
Annu Rev Public Health; 2006; 27():235-59. PubMed ID: 16533116
[TBL] [Abstract][Full Text] [Related]
28. Human vaccine research and development: an overview.
Kieny MP; Girard MP
Vaccine; 2005 Dec; 23(50):5705-7. PubMed ID: 16182415
[TBL] [Abstract][Full Text] [Related]
29. Vaccine manufacturing: challenges and solutions.
Ulmer JB; Valley U; Rappuoli R
Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
[TBL] [Abstract][Full Text] [Related]
30. The impact of globalization on vaccine development and availability.
Milstien JB; Kaddar M; Kieny MP
Health Aff (Millwood); 2006; 25(4):1061-9. PubMed ID: 16835187
[TBL] [Abstract][Full Text] [Related]
31. The expanding vaccine development pipeline, 1995-2008.
Davis MM; Butchart AT; Coleman MS; Singer DC; Wheeler JR; Pok A; Freed GL
Vaccine; 2010 Feb; 28(5):1353-6. PubMed ID: 19932670
[TBL] [Abstract][Full Text] [Related]
32. Introducing multiple vaccines in low- and lower-middle-income countries: issues, opportunities and challenges.
Gordon WS; Jones A; Wecker J
Health Policy Plan; 2012 May; 27 Suppl 2():ii17-26. PubMed ID: 22513729
[TBL] [Abstract][Full Text] [Related]
33. The need for new vaccines.
Taylor K; Nguyen A; Stéphenne J
Vaccine; 2009 Dec; 27 Suppl 6():G3-8. PubMed ID: 20006137
[TBL] [Abstract][Full Text] [Related]
34. New strategies for innovation in global health: a pharmaceutical industry perspective.
Witty A
Health Aff (Millwood); 2011 Jan; 30(1):118-26. PubMed ID: 21209447
[TBL] [Abstract][Full Text] [Related]
35. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
[TBL] [Abstract][Full Text] [Related]
36. U.S. childhood vaccine availability: legal, regulatory, and economic complexities.
Strongin RJ
NHPF Issue Brief; 2002 Nov; (785):1-20. PubMed ID: 12463233
[TBL] [Abstract][Full Text] [Related]
37. Contribution of the GAVI Alliance to improving health and reducing poverty.
Lob-Levyt J
Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2743-7. PubMed ID: 21893535
[TBL] [Abstract][Full Text] [Related]
38. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
Jadhav S; Datla M; Kreeftenberg H; Hendriks J
Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
[TBL] [Abstract][Full Text] [Related]
39. Strategies to advance vaccine technologies for resource-poor settings.
Kristensen D; Chen D
Vaccine; 2013 Apr; 31 Suppl 2():B157-62. PubMed ID: 23598477
[TBL] [Abstract][Full Text] [Related]
40. Challenges to building capacity for evidence-based new vaccine policy in developing countries.
Andrus JK; Jauregui B; De Oliveira LH; Ruiz Matus C
Health Aff (Millwood); 2011 Jun; 30(6):1104-12. PubMed ID: 21653964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
